Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases

 Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases

Acceleron’s ACE-083 Receives FDA’s ODD for Charcot Marie Tooth Disease (CMT)

Shots:

  • Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional payments $143.5M for all subsequent products commercialized plus royalties on sales of product
  • Acceleron to get rights to access Fulcrum’s product engine and target identification platform for identifying small molecule therapies controlling the expression of genes impacting specific pathways for pulmonary diseases and will take care of all development and commercial activities for developed products
  • The collaboration combines Fulcrum’s skill in identifying drug targets based on modulation of genetic pathways associated with disease and Acceleron’s deep expertise in TGF-beta for the generation of targeted therapies. Acceleron’s ACE-083 is a P-II locally acting myostatin+ agent targeted for Charcot-Marie-Tooth disease

Click here to read full press release/ article | Ref: Acceleron | Image: Signbox

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post